M&A

News

Vertex buys Crinetics for $10bn in endocrinology drive

Vertex has made the largest acquisition in its history, agreeing to buy Crinetics in a $10bn deal that adds an approved therapy for acromegaly.

News

Novartis snaps up UK ADC developer Myricx Bio

Novartis has reached a deal to buy Myricx Bio for up to $1.5bn, giving it control of the London, UK, start-up's ADC platform.

News

Ipsen's M&A team strikes again, adding Memo in $700m deal

Ipsen will pay up to €700m to take control of Memo Therapeutics and its drug for BK polyomavirus, which can lead to the failure of kidney transplants.

News

Zymeworks cuts deal to buy Theravance for $929m in cash

Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.

News

Ipsen charts $1.75bn course for Kartos acquisition

Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.

News

Merck buys life sciences firm Bio-Techne in $11.3bn deal

Merck KGaA is poised to increase the size of its life sciences business with an $11.3 billion deal to acquire rival Bio-techne.

Vertex buys Crinetics for $10bn in endocrinology drive

Novartis snaps up UK ADC developer Myricx Bio

Ipsen's M&A team strikes again, adding Memo in $700m deal

Zymeworks cuts deal to buy Theravance for $929m in cash

Ipsen charts $1.75bn course for Kartos acquisition

Merck buys life sciences firm Bio-Techne in $11.3bn deal

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

M&A

Editor's Picks